21110e07e06a326dc.EMJm-4z1iG4vxknNIbkKzk9SVuQm7yCx19-0GI_2F7g.WI0Jq9y75QACjxyLcdQ6hwk5PpJvrkv5p6fnIOmwb4tKi1-x9rTyCmeQAA
01:21pm Genomics Limited Announces Extension Of Strategic Drug Discovery Collaboration With Vertex Pharmaceuticals CI
11-17 Vertex Pharmaceuticals Incorporated Presents at Jefferies London Healthcare Conference, Nov-17-2026 05:00 PM
11-16 Vertex Pharmaceuticals Incorporated Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 09:20 AM
11-10 Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $640 From $556 MT
11-05 Vertex to Participate in Upcoming Investor Conferences BU
11-04 Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608 MT
11-03 Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says MT
11-03 UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615, Maintains Buy Rating MT
11-03 RBC Raises Price Target on Vertex Pharmaceuticals to $600 From $576, Keeps Outperform Rating MT
11-03 Stifel Adjusts Price Target on Vertex Pharmaceuticals to $563 From $500 MT
11-03 Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $660 From $665 MT
11-03 Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $660 From $558 MT
11-03 Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $619 From $595 MT
11-03 Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $725 From $654 MT
11-03 Barclays Adjusts Price Target on Vertex Pharmaceuticals to $626 From $617 MT
11-03 Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $650 From $550 MT
11-03 BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $620 From $600 MT
11-03 TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550 MT
11-03 JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $570 From $560 MT
11-03 Vertex Pharmaceuticals Incorporated, Q3 2026 Earnings Call, Nov 02, 2026
11-03 Vertex Pharmaceuticals Raises Outlook Following Crinetics Acquisition DJ
11-03 Vertex Pharmaceuticals Q3 Adjusted Earnings Fall, Revenue Rises MT
11-03 Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-03 Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q3 Revenue $3.44B, vs. FactSet Est of $3.42B MT
11-03 Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.76 per Share, vs. FactSet Est of $4.82 MT

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated